Quality of life after surgery for lower grade gliomas
- PMID: 37599093
- PMCID: PMC10872908
- DOI: 10.1002/cncr.34980
Quality of life after surgery for lower grade gliomas
Abstract
Background: Few large studies have investigated quality of life (QOL) for adults diagnosed with lower grade glioma (LGG).
Methods: QOL was assessed for 320 adults with LGG (World Health Organization grade 2/3) enrolled in the International Low Grade Glioma Registry by using the Medical Outcomes Study 36-Item Short Form health survey. Data on symptoms were also collected. QOL outcomes were examined by treatment group and also compared to those from a population-based case-control study of meningioma (the Meningioma Consortium), in which 1722 meningioma cases diagnosed among residents of Connecticut, Massachusetts, California, Texas, and North Carolina from May 1, 2006 through March 14, 2013 were enrolled and frequency matched to 1622 controls by age, sex, and geography.
Results: The LGG sample average age is 45 years at the time of interview and 53.1% male. Almost 55% of patients had received radiation and chemotherapy (primarily temozolomide); 32.4% had received neither treatment. Two-thirds of participants with LGG report difficulty with speaking, memory, or thinking, and over one of three reports personality change or difficulty driving. After controlling for age and other comorbidities, individuals with LGG report levels of physical, emotional, and mental health functioning below those reported in a meningioma as well as a general healthy population.
Conclusions: Despite being relatively young, persons with LGG report significantly reduced QOL compared to persons with nonmalignant brain tumors and to a control population, which highlights the need to better acknowledge and manage these symptoms for this group of patients diagnosed in the prime of life.
Keywords: astrocytoma; lower grade glioma; neuro-oncology; oligodendroglioma; quality of life; rehabilitation; symptom management.
© 2023 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.
Conflict of interest statement
Conflict of Interest Disclosure
The authors declare no conflicts of interest.
Similar articles
-
The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. doi: 10.3310/hta11450. Health Technol Assess. 2007. PMID: 17999840
-
Magnetic resonance perfusion for differentiating low-grade from high-grade gliomas at first presentation.Cochrane Database Syst Rev. 2018 Jan 22;1(1):CD011551. doi: 10.1002/14651858.CD011551.pub2. Cochrane Database Syst Rev. 2018. PMID: 29357120 Free PMC article.
-
Congress of Neurological Surgeons systematic review and evidence-based guidelines for the role of chemotherapy in newly diagnosed WHO Grade II diffuse glioma in adults: update.J Neurooncol. 2025 Jan;171(2):279-298. doi: 10.1007/s11060-024-04861-6. Epub 2024 Nov 20. J Neurooncol. 2025. PMID: 39565459
-
Tirzepatide and health-related quality of life in adults with obesity or overweight: Results from the SURMOUNT-3 phase 3 randomized trial.Diabetes Obes Metab. 2025 Aug;27(8):4268-4279. doi: 10.1111/dom.16463. Epub 2025 May 14. Diabetes Obes Metab. 2025. PMID: 40365662 Free PMC article. Clinical Trial.
-
Biopsy versus resection for the management of low-grade gliomas.Cochrane Database Syst Rev. 2017 Apr 27;4(4):CD009319. doi: 10.1002/14651858.CD009319.pub3. Cochrane Database Syst Rev. 2017. PMID: 28447767 Free PMC article.
Cited by
-
Estimating Health State Utilities for IDH-Mutant Diffuse Glioma.Pharmacoecon Open. 2025 Sep 6. doi: 10.1007/s41669-025-00603-0. Online ahead of print. Pharmacoecon Open. 2025. PMID: 40914782
-
Quality of life and symptom burden among hematologic malignancy patients undergoing CAR-T therapy: a cross-sectional study.Sci Rep. 2025 May 22;15(1):17763. doi: 10.1038/s41598-025-02720-6. Sci Rep. 2025. PMID: 40404866 Free PMC article.
-
Glioma resource outreach with support: A program to identify and initiate supportive care interventions for unmet needs among adult lower-grade glioma patients.Neurooncol Pract. 2024 Aug 5;12(1):87-99. doi: 10.1093/nop/npae065. eCollection 2025 Feb. Neurooncol Pract. 2024. PMID: 39917752 Free PMC article.
-
High costs, low quality of life, reduced survival, and room for improving treatment: an analysis of burden and unmet needs in glioma.Front Oncol. 2024 Mar 20;14:1368606. doi: 10.3389/fonc.2024.1368606. eCollection 2024. Front Oncol. 2024. PMID: 38571509 Free PMC article. Review.
-
Predicting cognitive function 3 months after surgery in patients with a glioma.Neurooncol Adv. 2025 May 2;7(1):vdaf081. doi: 10.1093/noajnl/vdaf081. eCollection 2025 Jan-Dec. Neurooncol Adv. 2025. PMID: 40575416 Free PMC article.
References
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical